Abstract
Purpose :
Elevated serum soluble interleukin 2 receptor (sIL-2R) is implicated in the diagnosis of ocular sarcoidosis. To confirm this notion, we performed a retrospective, case-control clinical study to investigate diagnostic value of serum sIL-2R in Japanese patients with ocular sarcoidosis.
Methods :
Medical records of 173 patients (71 men and 102 women with a mean age of 57 years) consisted of 31 patients with biopsy-proven sarcoidosis and 142 patients with other types of uveitis including Vogt-Koyanagi-Harada disease (n=8), herpetic anterior uveitis (n=13), acute anterior uveitis (n=11), vitreoretinal lymphoma (n=16), idiopathic granulomatous uveitis (n=52), and idiopathic non-granulomatous uveitis (n=42) as controls were reviewed. All the patients were newly consulted patients at uveitis clinic of TMDU hospital from 2014 to 2016, and tested for serum sIL-2 level. Data regarding the serum sIL-2R levels were collected, and compared between sarcoidosis and controls, and diagnostic parameters, i.e. sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were evaluated. Mann-Whitney U test was used for statistical analysis.
Results :
Serum sIL-2R level of biopsy-proven sarcoidosis (1063 ± 619 U/ml, mean ± SD) was significantly higher than that of the control group (440 ± 254 U/ml, P=7.4e-9) (Fig. 1). When sarcoidosis was compared to each disease entities in the controls, sarcoidosis showed higher sIL-2 level than any other disease entities. (Table 1) The incidences of serum sIL-2R level that exceeded the upper limit of the normal range (519 U/ml) were 77% in sarcoidosis and 25% in controls respectively. The diagnostic parameters of sIL-2R in the diagnosis of ocular sarcoidosis were calculated to be 0.77 for sensitivity, 0.75 for specificity, 0.41 for PPV, and 0.94 for NPV.
Conclusions :
Measurement of serum sIL-2R level have significant diagnostic value in patients with sarcoidosis.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.